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Introduction
Damage-associated molecular patterns (DAMPs) play important roles in in�lammation and immunity by functioning as signals of cell damage, stress or death during infection, injury or disease (Kono and Rock, 2008; Chen and Nuñez, 2010) . One of the best-characterised DAMP is extracellular adenosine 5'-triphosphate (ATP), which mediates its effects through the activation of the P2X7 purinergic receptor, a trimeric ATP-gated cation channel (Bours, et al., 2011; Wiley, et al., 2011) . Activation of P2X7 by extracellular ATP causes the �lux of Ca 2+ , Na + and K + , as well as the uptake of organic cations such as ethidium + and YO-PRO-1 2+ (Jarvis and Khakh, 2009 ). Furthermore, P2X7 activation induces various downstream events including the NALP3 in�lammasome-dependent maturation of IL-1β, and its subsequent release from various myeloid cell types (Di Virgilio, 2007) . This event, at least in monocytes, requires the prior activation of cells with the TLR4 ligand, LPS, which results in the upregulation and assembly of the NALP3 in�lammasome, as well as the synthesis of IL-1β (Mehta, et al., 2001; Bauernfeind, et al., 2009 ). Due to this and other properties of P2X7 activation, this receptor plays important roles in human health and disease , and thus may have similar roles in canine health and disease.
The presence of functional P2X7 on human and murine cell types is well established, but little is known about P2X7 in other mammalian species including the dog. We have previously demonstrated that peripheral blood monocytes, lymphocytes and erythrocytes from English Springer Spaniels express functional P2X7 (Sluyter, et al., 2007; Shemon, et al., 2008; Stevenson, et al., 2009 ). In particular, we have previously shown that the relative amount of P2X7 function in monocytes is about half that of canine T cells but similar to that of B cells (Stevenson, et al., 2009) . Similar studies in other dog breeds however are lacking, and given that distinct phenotypic traits exist between breeds it remains necessary to examine P2X7 in additional breeds. Moreover, it remains unknown if P2X7 activation can induce the release of IL-1β from canine monocytes, and there is a general paucity of studies examining IL-1β release from canine myeloid cell types. Given the importance of P2X7 in human health and disease , new knowledge about this receptor and events downstream of its activation in the dog is necessary to establish and understand the role of P2X7 in canine health and disease. Therefore, we investigated P2X7 in canine monocytes, and in particular its role in the release of IL-1β.
Materials and methods

Materials
Ficoll-Paque TM PLUS was from GE Healthcare Biosciences (Uppsala, Sweden). A438079 
Canine monocytes
Peripheral blood was collected into VACUETTE ® lithium heparin tubes (Greiner BioOne, Frickenheisen, Germany) from either pedigree or cross breed dogs with informed, signed consent of pet owners, and with the approval of the University of Wollongong Ethics Committee (Wollongong, Australia). PBMCs were isolated from buffy coats using Ficoll-monocytes, PBMCs in complete culture medium (RPMI-1640 medium containing 2 mM Lglutamine and 10% FCS) were incubated for 2 h at 37 o C/5% CO 2 , the non-adherent cells were removed by gently washing twice with PBS, and the plastic-adherent cells incubated for a further 4 h in complete culture medium containing 100 ng/ml LPS.
J774 cells
J774 cells (American Type Culture Collection, Rockville, MD), a murine macrophage cell line, were maintained in complete culture medium at 37 o C/5% CO 2 .
Reverse transcription PCR
Total RNA was isolated using the RNeasy ® Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Reverse transcription (RT)-PCR was performed using Superscript ® III One-Step RT-PCR System Platinum Taq DNA polymerase (Invitrogen) according to the manufacturer's instructions using primer pairs (GeneWorks, Hindmarsh, Australia) speci�ic for P2X7, NALP3, caspase-1 or IL-1β mRNA transcripts (Table 1 ). The identity of each transcript was con�irmed by sequencing of Exo-SAP-IT puri�ied amplicons using the above primer pairs with BigDye Terminator and an Applied Biosystems 3130xl Genetic Analyzer.
Immunoblotting
Immunoblotting of whole cell lysates was performed using a rabbit anti-rat P2X7 polyclonal Ab (Alomone Labs, Jerusalem, Israel) as described (Constantinescu, et al., 2010) .
Immunoblotting demonstrated that this Ab binds a protein corresponding to the predicted size of glycosylated P2X7 in HEK-293 cells transfected with canine P2X7 cDNA but not in mock-transfected HEK-293 cells (Spildrejorde and Sluyter, unpublished results).
YO PRO 1 2+ uptake assay
ATP-induced YO-PRO-1 2+ uptake into PBMCs suspended in NaCl medium (145 mM NaCl, 5 mM KCl, 5 mM glucose, 0.1% BSA, 10 mM HEPES, pH 7.4) was determined using a �ixed-time �low cytometric assay as described (Gadeock, et al., 2010) . To con�irm that ATPinduced YO-PRO-1 2+ uptake was mediated by P2X7, cells were pre-incubated in the absence or presence of 10 μM A438079 for 15 min. Following ATP incubation, cells were then labelled with PerCP/Cy5.5-or allophycocyanin-conjugated anti-human/canine CD14 mAb (clone M5E2) (BioLegend, San Diego, CA). To assess YO-PRO-1 2+ uptake in lymphocytes, cells were labelled with murine anti-canine CD21-like (clone CA2.1D6) or CD3 (clone CA17.2A12) mAb (AbD Serotec, Oxford, United Kingdom), and allophycocyanin-conjugated donkey anti-murine IgG (eBioscience, San Diego, CA). Data was acquired using a LSR II �low cytometer (BD) and the mean �luorescence intensity (MFI) of YO-PRO-1 2+ uptake determined using FlowJo software (Tree Star, Ashland, OR).
IL 1β release assay
ATP-induced IL-1β release from canine monocytes was performed as previously described for human monocytes (Sluyter, et al., 2004) . Brie�ly, PBMCs in complete culture medium were incubated in 24-well plates (0.625 x 10 6 cells/well) for 2 h at 37 o C/5% CO 2 .
Plates were washed and the plastic-adherent cells incubated for a further 4 h in complete culture medium containing 100 ng/ml LPS. The plastic-adherent cells were then preincubated in the absence or presence of 50 μM A438079 in RPMI-1640 medium containing 0.1% bovine serum albumin for 15 min, followed by incubation in the absence or presence of 5 mM ATP (0.5 ml/well) for 30 min. Following ATP incubation, samples were centrifuged (11,000 x g for 30 s) and cell-free supernatants stored at -20 o C until required. The amount of IL-1β in cell-free supernatants was quanti�ied using a Canine IL-1β VetSet TM ELISA Development Kit King�isher Biotech (St. Paul, MN) according to the manufacturer's instructions.
Statistical analysis
Differences between treatments were compared using either the unpaired Student's ttest or ANOVA (using Tukey's post test) for single or multiple comparisons, respectively.
Errors are expressed as SDs.
Results and discussion
P2X7 activation induces organic cation uptake into peripheral blood monocytes
To determine if P2X7 activation induces the uptake of an organic cation into monocytes from additional dog breeds to English Springer Spaniels, ATP-induced YO-PRO-1 2+ (375 Da) uptake into peripheral blood monocytes from two Staffordshire Bull Terriers and one Bull Terrier was examined in the absence or presence of A438079, which impairs human, monkey, rat and murine P2X7 (Donnelly-Roberts, et al., 2009; Bradley, et al., 2011) . In the absence of A438079, ATP induced YO-PRO-1 2+ uptake into peripheral blood monocytes from all three dogs (Fig. 1A) . Pre-incubation with this antagonist impaired ATP-induced YO-PRO-1 2+ uptake by 93 ± 13% (Fig. 1A) . Thus, P2X7 activation induces the uptake of YO-PRO-1 2+ into canine peripheral blood monocytes, and the presence of functional P2X7 receptors on peripheral blood monocytes is not restricted to one breed.
To determine the relative pattern of P2X7 function in leukocytes from various dog breeds other than English Springer Spaniels, ATP-induced YO-PRO-1 2+ uptake into peripheral blood monocytes from �ive different breeds was examined. As above (Fig. 1A) , ATP induced YO-PRO-1 2+ uptake into peripheral blood monocytes from each dog (Fig. 1B) . ATP also induced YO-PRO-1 2+ uptake into peripheral blood B and T cells from each dog, with the average amount of uptake three-fold greater in T cells compared to monocytes and B cells (range fold increase of 2.7-4.5 and 1.7-3.8, respectively) (Fig. 1B) . Thus, a relative pattern of P2X7 function similar to that observed for English Springer Spaniels (Stevenson, et al., 2009) is also seen between peripheral blood monocytes, B cells and T cells from �ive other dog breeds (Australian Bulldog, Border Collie, Bull Terrier, Jack Russell Terrier and Staffordshire
Bull Terrier). The difference between canine monocytes, B cells and T cells most likely relates
to the amount of P2X7 expression, as cell-surface P2X7 expression correlates with P2X7 function in human leukocytes (Gu, et al., 2000) . Moreover, the consistent pattern of P2X7 function between leukocyte subsets from the various breeds suggests that the regulation of P2X7 expression is highly conserved within dogs. The pattern of P2X7 function between leukocyte subsets from humans is also similar however, in contrast to dogs, P2X7 function is �ive-fold higher in human peripheral blood monocytes compared to human peripheral blood B or T cells (Gu, et al., 2000; Stevenson, et al., 2009) . Whether these differences between the two species are of physiological signi�icance remain unknown. Nevertheless, despite these species dissimilarities, it appears likely that functional P2X7 receptors are expressed on peripheral blood monocytes, B cells and T cells from all dog breeds.
P2X7 activation induces organic cation uptake into and IL 1β release from LPS primed monocytes
To determine if P2X7 can induce the release of IL-1β from canine monocytes, the presence of mRNA transcripts for P2X7 and IL-1β, as well as for the NALP3 in�lammasome components, NALP3 and caspase-1, were examined in LPS-primed canine monocytes. RT-PCR demonstrated the presence of mRNA transcripts for all four molecules ( Fig. 2A) , with transcripts corresponding to the predicted size (Table 1) for each molecule (results not shown). Moreover, with the exception of IL-1β (due to its small size of 64 bp), the identity of each transcript was con�irmed by sequencing (results not shown). No PCR products were observed in the water control ( Fig. 2A) .
To determine if LPS-primed canine monocytes express functional P2X7, the presence of P2X7 protein was examined by immunoblotting. Murine J774 macrophages, which express P2X7 (Coutinho-Silva, et al., 2005) , were used as a positive control. Immunoblotting with an anti-P2X7 Ab demonstrated the presence of a major band at 75 kDa, the predicted size of glycosylated P2X7, in both cell types (Fig. 2B) . Minor bands were also observed at 60 and 68 kDa in LPS-primed canine monocytes and J774 cells, respectively (Fig. 2B) . These minor bands most likely represent a degradation product and non-glycosylated P2X7, respectively.
To con�irm that P2X7 was functional in LPS-primed canine monocytes, ATP-induced YO-PRO-1 2+ uptake was examined in the absence or presence of A438079. In the absence of A438079, ATP induced YO-PRO-1 2+ uptake into LPS-primed canine monocytes (Fig. 2C) . Preincubation with this antagonist impaired ATP-induced YO-PRO-1 2+ uptake by 97 ± 4% (Fig. 2C ). A438079 in the absence of ATP had no signi�icant effect on YO-PRO-1 2+ uptake compared to YO-PRO-1 2+ uptake in the absence of both A438079 and ATP (results not shown). Thus, LPS-primed canine monocytes from two pure breeds (Australian Kelpie and two Labradors) and from one cross breed (Border Collie cross Australian Cattle Dog) express functional P2X7 receptors.
Finally, to determine if P2X7 activation induces IL-1β release from LPS-primed canine monocytes, cells were pre-incubated in the absence or presence of A438079 prior to incubation in the absence or presence of ATP, and the amount of IL-1β in cell-free supernatants measured using a canine IL-1β ELISA. In the absence of A438079, ATP induced IL-1β release from LPS-primed canine monocytes (Fig. 2D) . Pre-incubation with this antagonist impaired ATP-induced IL-1β release by 97 ± 9% (Fig. 2D) . A438079 in the absence of ATP had no signi�icant effect on IL-1β release compared to IL-1β release in the absence of both A438079 and ATP (results not shown). Thus, P2X7 activation induces the release of IL-1β from LPS-primed canine monocytes. To the best of our knowledge, the P2X7-induced IL-1β release from canine monocytes has not been previously reported, however others, using peripheral blood from Beagles, have shown that P2X7 activation induces IL-1β release in a whole-blood assay (Roman, et al., 2009) . Collectively, these observations are consistent with �indings with human monocytes or whole blood (Perregaux, et al., 2000; Mehta, et al., 2001; Sluyter, et al., 2004; Bauernfeind, et al., 2009) , and indicate that P2X7 may also play an important role in IL-1β-dependent processes in dogs.
P2X7 and the NALP3 in�lammasome in canine health and disease
P2X7 has an established role in in�lammation and immunity (Bours, et al., 2011; Wiley, et al., 2011) , and related disorders that include in�lammatory arthritis, and neuropathic and in�lammatory pain (Labasi, et al., 2002; Chessell, et al., 2005) . The action of P2X7 in these circumstances is largely attributed to its release of IL-1β from monocytes and macrophages, although other in�lammatory mediators may also be involved .
Nonetheless, P2X7 is attracting considerable interest as a therapeutic target in humans (Donnelly-Roberts and Jarvis, 2007; Arulkumaran, et al., 2011) , and it is likely that compounds that target P2X7 will have similar therapeutic bene�its in dogs. The results also support the use of the dog as a suitable model to study the role of P2X7 in health and disease, as well as to test the therapeutic ef�icacy and other pharmacological parameters of P2X7 antagonists before commencing human clinical trials. In regard to this latter point, dogs have been used to test the bioavailability and half-life of potential P2X7 antagonists for use as therapeutics in humans (Abberley, et al., 2010; Duplantier, et al., 2011) .
Conclusion
The current study demonstrates that functional P2X7 receptors are present in peripheral blood monocytes from various breeds, and that the relative P2X7 function in these cells is about half that of peripheral T cells but similar to that of peripheral blood B cells.
Moreover, the study demonstrates that LPS-primed canine monocytes produce mRNA transcripts for P2X7 and IL-1β, as well as for the NALP3 in�lammasome components, NALP3
and caspase-1. Finally, the study demonstrates that these cells express P2X7 protein, and that activation of this receptor induces the uptake of the organic cation, YO-PRO-1 2+ , and the release of IL-1β. Collectively, these results show that dogs express functional P2X7 receptors, and that this receptor may play important roles in canine health and disease, and thus may represent a promising therapeutic target in dogs.
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